Phase 1 Study of Linvemastat (FP-020) in Healthy Volunteers

Phase 1, randomised, double-blind trial of linvemastat in asthma, chronic obstructive pulmonary disease (COPD) and inflammatory bowel disease (IBD) (5 arms), sponsored by Foresee Pharmaceuticals. Primary endpoints: Incidence, severity, and type of Adverse Events (AEs) and Serious Adverse Events (SAEs) up to 17 days and Clinically significant abnormalities up to 17 days. Started Apr 2024; status: completed.